RT Journal Article
SR Electronic
T1 Limits and opportunities of SARS-CoV-2 antigen rapid tests – an experience based perspective
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.22.20199372
DO 10.1101/2020.09.22.20199372
A1 Verena Schildgen
A1 Sabrina Demuth
A1 Jessica Lüsebrink
A1 Oliver Schildgen
YR 2020
UL http://medrxiv.org/content/early/2020/10/30/2020.09.22.20199372.abstract
AB Background Due to the steadily rising case numbers of SARS-CoV-2 infections worldwide there is an increasing need for reliable rapid diagnostic devices in addition to existing gold standard PCR-methods. Actually, public attention is focused on antigen assays including lateral flow tests (LFTs) as diagnostic alternative. Therefore, different LFTs were analyzed regarding their performance in a clinical setting.Material and Methods A pilot sample panel of 13 BALFs and 60 throat washing samples (TWs) with confirmed PCR results as well as 8 throat washes invalid by PCR was tested with the BIOCREDIT test (RapiGEN), the Panbio™ assay (Abbott), and the SARS-CoV-2 Rapid Antigen Test (Roche).Conclusion The analyzed antigen test showed an inter-assay correlation of 27.4% with overall specificities ranging from 19.4% to 87.1%, while sensitivities of the respective tests ranged between 33.3% and 88.1%. Although these assays did not entirely meet all high expectations their benefit has to be carefully evaluated for the respective test strategy and setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo Funding was available for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Vote 122/2016 Ethical Committee of the Private University of Witten/HerdeckeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the manuscript.